Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.63 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.63 |
| ▸ | ACP1 | P24666 | 1/20 | 0.63 |
| ▸ | PDE4A | P27815 | 1/20 | 0.63 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.63 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.63 |
| ▸ | PNPO | Q9NVS9 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | SGPL1 | O95470 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.37 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.36 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyridoxamine Phosphate Anhydrous SCHEMBL29619879 | 1.00 | ESR1 (0.63) | ESR1PTGS1ACP1PDE4AP2RX1 | |
| Pyridoxamine Phosphate Anhydrous SCHEMBL10942609 | 0.99 | ESR1 (0.61) | ESR1PTGS1ACP1PDE4AP2RX1 | |
| SCHEMBL16171284 | 0.90 | LMNA (0.57) | ESR1PTGS1ACP1PDE4AP2RX1 | |
| SCHEMBL2683971 | 0.90 | LMNA (0.60) | ESR1PTGS1ACP1PDE4AP2RX1 | |
| SCHEMBL13176882 | 0.87 | ESR1 (0.64) | ESR1PTGS1ACP1PDE4AP2RX1 | |
| SCHEMBL29384180 | 0.87 | ESR1 (0.64) | ESR1PTGS1ACP1PDE4AP2RX1 | |
| SCHEMBL43880 | 0.87 | ESR1 (0.64) | ESR1PTGS1ACP1PDE4AP2RX1 | |
| Water SCHEMBL371432 | 0.86 | ESR1 (0.63) | ESR1PTGS1ACP1PDE4AP2RX1 | |
| Ammonia Solution, Strong SCHEMBL31241292 | 0.86 | ESR1 (0.63) | ESR1PTGS1ACP1PDE4AP2RX1 | |
| SCHEMBL16420385 | 0.86 | ESR1 (0.63) | ESR1PTGS1ACP1PDE4AP2RX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1807 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122081007-A | Extraction method and application of lysimachia foenum-graecum volatile oil | — | 2026-05-26 | — | — | CN | claimed |
| WO-2026085618-A1 | METHOD OF IMMOBILIZING CAPTURE PROBES TO SOLID PHASES FOR TARGET SUBSTANCE DETECTION | YYZ PHARMATECH INC. (CA) | 2026-04-30 | — | — | WO | claimed |
| US-20250302964-A1 | Topical Compositions and Methods for Treatment of Diabetic Neuropathies | CROSS III WILLIAM H (US) | 2025-10-02 | — | — | US | claimed |
| EP-4601627-A1 | COMPOSITION COMPRISING NOT PHOSPHORYLATED TRYPTAMINE, ANTIOXIDANTS, AND SUPPLEMENTS, AND PHARMACEUTICAL USES THEREOF | Sintalica S.r.l. (IT) | 2025-08-20 | — | — | EP | claimed |
| CN-119792284-A | Application of vitamin B6 in preparing medicine for preventing and/or treating NLRP6 inflammation small body overactive state diseases | 中国科学技术大学 | 2025-04-11 | — | — | CN | claimed |
| CN-119285924-A | Nicotinic acid modified pyridoxamine polyether polyol and preparation method thereof | 山东一诺威新材料有限公司 | 2025-01-10 | — | — | CN | claimed |
| WO-2024252346-A1 | CONTINUOUS RECYCLABLE ENZYMATIC PROCESS FOR PREPARATION OF SITAGLIPTIN OR SALTS THEREOF | AMI LIFESCIENCES PRIVATE LIMITED (IN) | 2024-12-12 | — | — | WO | claimed |
| CN-119082097-A | Immobilized L-cysteine synthetase, and preparation method and application thereof | 黑龙江新和成生物科技有限公司 | 2024-12-06 | — | — | CN | claimed |
| CN-117789993-B | Establishment and application of gastric cancer prediction model based on tongue fur metabolite | 浙江省肿瘤医院 | 2024-06-11 | — | — | CN | claimed |
| US-20240180891-A1 | SYNERGISTIC MODULATORS OF ALPHA-DICARBONYL DETOXIFICATION AND THEIR USE FOR INDUCING WEIGHT LOSS AND THE TREATMENT OF DIABETIC PATHOLOGIES | BUCK INSTITUTE FOR RESEARCH ON AGING (US) | 2024-06-06 | — | — | US | claimed |
| EP-0540687-A4 | ANTIBODY-MEDIATED COFACTOR-DRIVEN REACTIONS | — | 1993-10-13 | — | — | EP | claimed |
| EP-0540687-A1 | ANTIBODY-MEDIATED COFACTOR-DRIVEN REACTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1993-05-12 | — | — | EP | claimed |
| EP-0282696-B1 | USE OF PYRIDOXINE DERIVATIVES IN THE PROPHYLAXIS AND TREATMENT OF HYPERLIPEMIA AND ATHEROSCLEROSIS | STEIGERWALD ARZNEIMITTELWERK GMBH (DE) | 1992-11-11 | — | — | EP | claimed |
| US-5160725-A | Contrast agent for diagnostic imaging, polyethylene glycol phosphates and carboxylates as stabilizers | SILICA GEL GESELLSCHAFT MBH ADSORPTIONS-TECHNIK, APPARATEBAU (DE) | 1992-11-03 | — | — | US | claimed |
| EP-0495270-A1 | Azaribine composition | Drell, William, Dr. (US) | 1992-07-22 | — | — | EP | claimed |
| EP-0284549-B1 | MAGNETIC FLUID COMPOSITIONS | Silica Gel Ges.mbH Absorptionstechnik, Apparatebau (DE) | 1992-07-15 | — | — | EP | claimed |
| WO-1992001781-A1 | ANTIBODY-MEDIATED COFACTOR-DRIVEN REACTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1992-02-06 | — | — | WO | claimed |
| US-5023083-A | Azarbine composition | DRELL WILLIAM (US) | 1991-06-11 | — | — | US | claimed |
| EP-0379936-A2 | Pyridoxal for use in enzyme deficiencies, and a diagnostic kit for their diagnosis | VESTA MEDICINES (PROPRIETARY) LIMITED (ZA) | 1990-08-01 | — | — | EP | claimed |
| EP-0106813-A2 | Pharmaceutical utilisation of 3-indolpyruvic acid | POLIFARMA S.p.A. (IT) | 1984-04-25 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240180891-A1 | SYNERGISTIC MODULATORS OF ALPHA-DICARBONYL DETOXIFICATION AND THEIR USE FOR INDUCING WEIGHT LOSS AND THE TREATMENT OF DIABETIC PATHOLOGIES | PDXK, PLPBP, GLS | ESR1 4425/4885PTGS1 423/4885ACP1 3251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.